Comparative Pharmacology
Head-to-head clinical analysis: ANCEF versus TAZIDIME IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF versus TAZIDIME IN PLASTIC CONTAINER.
ANCEF vs TAZIDIME IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP-3, leading to cell lysis and death. It is a beta-lactam antibiotic with activity against Gram-negative bacteria including Pseudomonas aeruginosa.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
1-2 g intravenously every 8 hours for most infections; up to 2 g every 6 hours for severe infections, particularly in neutropenic patients or those with cystic fibrosis.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
Terminal elimination half-life 1.7-2.0 hours in adults with normal renal function; prolonged to 12-30 hours in end-stage renal disease.
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for <1%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic